Summary
We have previously shown that, in asymptomatic post-menopausal women, serum CA125 elevation is associated with a 36-fold increase in risk of ovarian cancer. This study was undertaken to assess the value of pelvic ultrasound for further stratification of ovarian cancer risk. Of 22 000 post-menopausal women, aged ≥ 45 participating in an Ovarian Cancer Screening Trial, 741 with a CA125 ≥ 30 U ml–1 underwent pelvic ultrasonography. Twenty index cancers (primary invasive epithelial carcinomas of the ovary and fallopian tube) were diagnosed amongst these 741 women during a median follow-up of 6.8 years. Ultrasound results separated the women with CA125 elevation into two groups. Those with normal ovarian morphology had a cumulative risk (CR) of index cancer of 0.15% (95% confidence interval (CI) 0.02–1.12) which is similar to that of the entire population of 22 000 women (0.22%, 95% CI 0.18–0.30). In contrast, women with abnormal ovarian morphology had a CR of 24% (15–37) and a significantly increased relative risk (RR) of 327 (156–683). Ultrasound can effectively separate post-menopausal women with raised CA125 levels into those with normal scan findings who are not at increased risk of index cancer and those with abnormal findings who are at substantially increased risk of index cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Campbell, S., Bhan, V., Royston, P., Whitehead, M. I. & Collins, W. P. (1989). Transabdominal ultrasound screening for early ovarian cancer. Br Med J 299: 1363–1367.
Gadducci, A., Zola, P., Landoni, F., Maggino, T., Sartori, E., Bergamino, T. & Cristofani, R. (1995a). Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 58: 42
Jacobs, I. J., Stabile, I., Bridges, J., Kemsley, P., Reynolds, C., Grudzinskas, J. & Oram, D. (1988). Multimodal approach to screening for ovarian cancer. Lancet 1: 268–271.
Jacobs, I. J., Oram, D., Fairbanks, J., Turner, J., Frost, C. & Grudzinskas, J. G. (1990). A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 97: 922–929.
Jacobs, I. J., Davies, A. P., Bridges, J., Stabile, I., Fay, T., Lower, A., Grudzinskas, J. G. & Oram, D. (1993). Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br Med J 306: 1030–1034.
Jacobs, I. J., Skates, S., Davies, A. P., Woolas, R. P., Jeyerajah, A., Weidemann, P., Sibley, K. & Oram, D. H. (1996). Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. Br Med J 313: 1355–1358.
Nagele, F., Petru, E., Medl, M., Kainz, C., Graf, A. H. & Sevelda, P. (1995). Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 86: 259–264.
Rothman, K. J. (1986). Modern Epidemiology, pp. 218. Little Brown: Boston
Rustin, G. J., Nelstrop, A. E., McClean, P., Brady, M. F., McGuire, W. P., Hoskins, W. J., Mitchell, H. & Lambert, H. E. (1996a). Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14: 1545–1551.
Rustin, G. J., Nelstrop, A. E., Tuxen, M. K. & Lambert, H. E. (1996b). Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group Study. Ann Oncol 7: 361–364.
Tingulstad, S., Hagen, B., Skjeldestad, F. E., Onsrud, M., Kiserud, T., Halvorsen, T. & Nustad, K. (1996). Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 103: 826–831.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Menon, U., Talaat, A., Jeyarajah, A. et al. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br J Cancer 80, 1644–1647 (1999). https://doi.org/10.1038/sj.bjc.6690575
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690575
Keywords
This article is cited by
-
Screening, epidemiology, molecular biology, and treatment strategies for endometriosis‐associated ovarian cancer
Reproductive Medicine and Biology (2010)
-
Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis
International Journal of Clinical Oncology (2009)
-
Treatment guidelines in ovarian cancer
Clinical and Translational Oncology (2007)
-
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
British Journal of Cancer (2004)